Why the study?
Hormones modulate cardiac electrophysiology, and GnRHa and GAHT may impact QTc intervals with potential clinical implications.
Do gonadotropin-releasing hormone agonists and gender-affirming hormonal treatment alter QTc intervals in transgender/gender-diverse adolescents?
Do gonadotropin-releasing hormone agonists and gender-affirming hormonal treatment alter QTc intervals in transgender/gender-diverse adolescents?
Gender-affirming hormonal treatments alter QTc intervals in transgender adolescents, with GnRHa prolonging QTc in females and testosterone decreasing QTc in males.
May warrant QTc monitoring in TGD adolescents on GnRHa or testosterone; observational data leave open arrhythmia risk and need for prospective trials.
: Hormones play a significant role in modulating cardiac electrophysiology. Gonadotropin-releasing hormone agonists (GnRHa) and gender-affirming hormonal treatment (GAHT) may impact QTc intervals, which could have clinical implications. Aim: To evaluate QTc interval changes in transgender/gender-diverse (TGD) adolescents undergoing GnRHa and GAHT. Methods: This prospective study included 39 TGD adolescents (20 females), mean age 15.6 ± 1.4 years, Tanner stage 4-5. QTc intervals were measured before and after GnRHa treatment and following GAHT initiation. Two participants, prescribed psychiatric medications exhibited a borderline/short QTc after adding testosterone. No arrhythmias were observed. Discussion and conclusion: QTc prolongation was observed in TGD female adolescents after the initiation of GnRHa, while TGD males showed a decrease in QTc following testosterone administration. Further studies on the clinical implications of QT interval changes in this population are warranted.
No takes yet. Share an insight, caveat, or question.
Zaitoon et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: